Cost–effectiveness of pregabalin: a UK perspective

References

• Taylor CP. The biology and pharmacology of calcium channel a2-d proteins. CNS Drug Rev.10, 183–188 (2004).
   PubMedGoogle Scholar
• Fink K, Dooley DJ, Meder WP et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology42, 229–236 (2002).
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of gabapentin and pregabalin at P? Q-type voltage-sensitive calcium channels: inhibition of K+ 3H-norepinephrine release from rat neocortical slices. Synapse45, 171–190 (2002).
   PubMed Web of Science ®Google Scholar
• Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain105, 133–141 (2003).
   PubMed Web of Science ®Google Scholar
• Bailer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res.73, 1–52 (2007).
   PubMed Web of Science ®Google Scholar
• Leach JP. Pregabalin – a new treatment for partial epilepsy and neuropathic pain. ACNR4(6), 33–34 (2005).
   Google Scholar
• French JA, Kugler AR, Robbins JL et al. Dose–response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology60, 1631–1637 (2003).
   PubMed Web of Science ®Google Scholar
• Arroyo S, Anhut H, Kugler AR et al. The Pregabalin 1009–011 International Study Group. Pregabalin add-on treatment: a randomised double-blind placebo-controlled dose–response study in adults with partial seizures. Epilepsia45, 20–27 (2004).
   PubMed Web of Science ®Google Scholar
• Beydoun A, Uthman BM, Kugler AR et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology64, 475–480 (2005).
   PubMed Web of Science ®Google Scholar
• Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed dose treatment in a double-blind, placebo-controlled study. Epilepsia46(12), 1926–1936 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatowski R, Galvez R, Cherry DA et al.; 1008–045 Study Group. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain109(1–2), 26–35 (2004).
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Corbin AE, Young JP et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology60, 1274–1283 (2003).
   PubMed Web of Science ®Google Scholar
• Van Seventer R, Feister HA, Young JP et al. Efficacy and tolerability of twice daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr. Med. Res. Opin.22(2), 375–384 (2006).
   PubMed Web of Science ®Google Scholar
• Richter RW, Portenoy R, Sharma U et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J. Pain6(4), 253–260 (2005).
   PubMed Web of Science ®Google Scholar
• Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology63(11), 2104–2110 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain110(3), 628–638 (2004).
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of twice-daily pregabalin in the treatment of patients with chronic neuropathic pain evaluated with a novel study design: a 12-week, randomised, double-blind, multicentre, placebo-controlled evaluation of flexible- and fixed-dose regimens of pregabalin. Pain115(3), 254–263 (2005).
   PubMed Web of Science ®Google Scholar
• Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med.10(7), 685–692 (2004).
   PubMed Web of Science ®Google Scholar
• Pande AC, Crockatt JG, Feltner DE et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am. J. Psychiatry160(3), 533–540 (2003).
   PubMed Web of Science ®Google Scholar
• Mula M, Pini S, Cassano GB. The role of anticonvulsant in anxiety disorders: a critical review of the evidence. J. Clin. Psychopharmacol.27(3), 263–272 (2007).
   PubMed Web of Science ®Google Scholar
• Tarride J, Gordon A, Monyserrat V-L, Dukes E, Rousseau C. Cost–effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin. Ther.11, 1922–1934 (2006).
   Google Scholar
• Sirvein JI, Fife TD, Wingerchuk DM, Drazkowski MD. Second-generation antiepileptic drugs’ impact on balance: a meta-analysis. Mayo Clin. Proc.82(1), 40–47 (2007).
   PubMed Web of Science ®Google Scholar
• Smith KJ, Roberts MS. Sequential medication strategies for postherpetic neuralgia: a cost–effectiveness analysis. J. Pain5, 396–404 (2007).
   Google Scholar
• Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst. Rev.CD005451 (2005).
   Google Scholar
• Hachinski V. New antiepileptic drugs: the cost of innovation. Arch. Neurol.55(8), 1142 (1998).
   PubMedGoogle Scholar
• Walker MC, SanderJW. Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs. Neurology49(2), 333–337 (1997).
   PubMed Web of Science ®Google Scholar
• Heaney D, Sander JW. The cost–effectiveness of carbamazepine in epilepsy. Expert Rev. Pharmacoeconomics Outcomes Res.6(1), 13–18 (2006).
   PubMedGoogle Scholar
• Chadwick D. Do new antiepileptic drugs justify their expensive? Arch. Neurol.55, 1140–1142 (1998).
   PubMedGoogle Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet369(9566), 1000–1015 (2007).
   PubMed Web of Science ®Google Scholar
• Gilron I, Coderre TJ. Emerging drugs in neuropathic pain. Expert Opin. Emerg. Drugs12(1), 113–126 (2007).
   PubMed Web of Science ®Google Scholar
• Regional drug and Therapeutics Centre. New Drug Evalution: Pregabalin for neuropathic pain. Regional drug and Therapeutics Centre, Newcastle Upon Tyne, UK, No. 66 (2004).
   Google Scholar